Clinical News

A close look at their potential to interact with other medications is required to limit the risk of adverse outcomes for patients.

Approximately 20% to 30% of men with metastatic castration-resistant prostate cancer have HRR gene mutation.

Fam-trastuzumab deruxtecan-nxki (Enhertu, Daiichi Sankyo) is indicated for treating adults with unresectable or metastatic HER2-positive breast cancer who have received 2 or more prior anti-HER2–based regimens in the setting of metastasis.

Investigators are evaluating a variety of medications for the novel coronavirus disease 2019 (COVID- 19), and the possible treatment landscape is rapidly evolving.

Never before have so many brilliant minds, machines, and groups come together so quickly in an attempt to develop a vaccine.

In July 2019, the FDA approved darolutamide (Nubeqa, Bayer) for men with prostate cancer that has not spread (ie, nonmetastatic) and no longer responds to medical or surgical treatment that lowers testosterone (ie androgen deprivation therapy).

Hydroxychloroquine has been widely used for treatment of COVID-19, despite the lack of strong evidence supporting its efficacy.

In August 2019, the FDA approved entrectinib for treatment of adult patients with metastatic non-small cell lung cancer that is ROS1-positive.

Apremilast (Otezla, Amgen) significantly improved psoriasis symptoms compared with a placebo in adults with mild-to-moderate disease.

Officials with the FDA have approved dapagliflozin (Farxiga, AstraZeneca) to reduce the risk of cardiovascular death and hospitalization in adults with heart failure with reduced ejection fraction, with and without type 2 diabetes.

A new study evaluated methods of improving heart function in individuals with type 2 diabetes.

Officials with the FDA approved niraparib (Zejula, GlaxoSmithKline), a once-daily, oral monotherapy, for the first-line maintenance treatment of platinum-responsive advanced ovarian cancer regardless of biomarker status.

New clinical trial updates on remdesivir as a potential treatment for coronavirus disease 2019 (COVID-19) were announced today.

Building literature evaluation skills is an essential teaching component during all stages of pharmacy education

Six-year data from the new analyses add evidence to the benefit-risk profile of ocrelizumab (Ocrevus, Genentech) for patients with multiple sclerosis. 

Regeneron and Sanofi will amend their ongoing trial of sarilumab (Kevzara) to enroll only “critical” hospitalized patients with COVID-19.

The FDA warned against the use of hydroxychloroquine and chloroquine outside of the hospital setting or clinical trials due to safety risks. 

Two new studies underscore health disparities in rural United States affecting mortality rates associated with cardiovascular disease.

Officials with the FDA have granted accelerated approval to sacituzumab govitecan-hziy (Trodelvy, Immunomedics Inc.) for previously-treated adult patients with metastatic triple-negative breast cancer.

Siponimod (Mayzent, Novartis) had a sustained effect on slowing disability progression in patients with secondary progressive multiple sclerosis (SPMS), according to new long-term data from a phase 3 study.

The guidelines provide clinical recommendations to providers treating patients with coronavirus disease 2019 (COVID-19).

The study examined the effects of unprotected, prolonged patient contact, along with certain exposures, on the risk of health care providers becoming infected with COVID-19.

Genentech is seeking approval for a 2-hour ocrelizumab (Ocrevus) infusion time in patients with relapsing or primary progressive multiple sclerosis.

Officials with the FDA today approved tucatinib (Tukysa, Seattle Genetics) in combination with chemotherapy trastuzumab and capecitabine for the treatment of adults with advanced forms of HER2-positive breast cancer.

A recent meta-analysis showed an association between regular aspirin use and reduced risk of developing several cancers of the digestive tract.

Gilead shares compassionate use data for remdesivir in patients with COVID-19 and a new research paper suggests remdesivir's mechanism of action could make it effective in combatting the virus. 

New research has identified an association between sensory loss and novel coronavirus 2019 (COVID-19) infection.

A clinical trial evaluating the safety and efficacy of hydroxychloroquine in hospitalized patients with COVID-19 has begun.

In 2010, nearly 43 million of adults living in the United States, or approximately 20%, took aspirin a minimum of 3 times per week for 3 months or more.

Children with the novel coronavirus disease 2019 (COVID-19) may not develop a fever or cough as often as adults with the virus.